Response to: Cutaneous papillary adenocarcinoma in situ

Abstract

REFERENCES1. Goto K, Takai T, Fukumoto T, et al. CD117 (KIT) is a useful immunohistochemical marker for differentiating porocarcinoma from squamous cell carcinoma. J Cutan Pathol. 2016;43:219-226. 2. Goh SGN, Dayrit JF, Calonje E. Sarcomatoid eccrine porocarcinoma: report of two cases and a review of the literature. J Cutan Pathol. 2007;34:55-60. 3. Le MD, Hassan K, Cassarino DS. Biphasic sarcomatoid porocarcinoma. Am J Dermatopathol. 2016;38:73-76. 4. Kazakov DV, Kutzner H, Spagnolo DV, et al. Sebaceous differentiation in poroid neoplasms: report of 11 cases, including a case of metaplastic carcinoma associated with apocrine poroma (sarcomatoid apocrine porocarcinoma). Am J Dermatopathol. 2008;30:21-26. 5. Patel NK, McKee PH, Smith NP, Fletcher CDM. Primary metaplastic carcinoma (carcinosarcoma) of the skin: a clinicopathologic study of four cases and review of the literature. Am J Dermatopathol. 1997;19:363-372. 6. Ponzetti A, Ribero S, Caliendo V, Spadi R, Macripo G, Lista P. Long-term survival after multidisciplinary management of a metastatic sarcomatoid porocarcinoma with repeated exeresis, radiotherapy, chemotherapy and cetuximab: case report and review of literature. G Ital Dermatol Venereol. 2017;152:66-70. 7. Goto K. Immunohistochemistry for CD117 (kit) is effective in distinguishing cutaneous adnexal tumors with apocrine/eccrine or sebaceous differentiation from other epithelial tumors of the skin. J Cutan Pathol. 2015;42:480-488. 8. Martland G, Goodman A, Shepherd N. CD117 expression in oesophageal carcinosarcoma: a potential diagnostic pitfall. Histopathology. 2004;44:77-80."AIS" (if such an entity truly exists) to be gathered, studied and critically evaluated.